Regulation of the Function of αvβ3 in Platelets by a Designed Peptide Targeting the αv Transmembrane Domain.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1504-1504
Author(s):  
Hang Yin ◽  
Joanna S. Slusky ◽  
Bryan W. Berger ◽  
Rustem I. Litvinov ◽  
Gaston Vilaire ◽  
...  

Abstract Integrins reside on cell surfaces in an equilibrium between inactive and active conformations. When inactive, the transmembrane (TM) domains of integrin α and β subunits interact, but the domains separate when integrins assume their active conformation. Although this conformational change has not been shown for αvβ3, we hypothesized that a peptide designed to bind to the αv TM domain might activate αvβ3 in platelets by disrupting the TM domain heterodimer of the inactive molecule. To design such a peptide, we used CHAMP (Computed Helical Anti-Membrane Protein) methodology. In the CHAMP method, the αv TM helix was scanned for motifs likely to mediate αvβ3 TM domain interactions. Next, the backbone conformation for an αv-binding peptide was selected based on known structural preferences for the motifs identified in the αv helix. Finally, the sequence for the peptide was designed computationally using a side-chain repacking algorithm. The CHAMP peptide, anti-αv, and its TM helix target, αv-TM, were synthesized by solid phase synthesis. We also synthesized anti-αvmut in which the putative anti-αv-TM binding motif, GXXXG, was mutated to LXXXL. Lys2 dipeptides and short polyethylene glycol sequences were appended to the C- and N-termini of the peptides, respectively, to facilitate their solubility and insertion into membranes. CD spectroscopy revealed that both anti-αv and αv-TM were helical in micelles and phospholipid vesicles. Measurement of Trp fluorescence intensity revealed that anti-αv rapidly inserted into unilamellar POPC/POPG vesicles. Analytical ultracentrifuge and fluorescence resonance energy transfer experiments demonstrated that anti-αv bound to the αv-TM, but not to a homologous αIIb-TM domain peptide. In addition, there was negligible interaction between αv-TM and anti-αvmut. Anti-αv also formed heteromeric complexes with the αv TM domain in bacterial membranes but not with the TM domains of αIIb, α2, β1, or β3. αvβ3 mediates the adhesion of agonist-stimulated platelets to the matrix protein osteopontin (OPN). We found that anti-αV at μM concentrations induced platelet adhesion to OPN. Adhesion was prevented by the divalent cation chelator EDTA, consistent with an integrin-mediated process, but was only minimally affected by pre-incubating the platelets with PGE1, implying that anti-αv-induced adhesion by interacting directly with the αv TM domain. Force spectroscopy using laser tweezers confirmed the specificity of the interaction of anti-αv with platelets: anti-αv induced specific rupture forces between platelets and OPN-coated beads, but not between platelets and fibrinogen-coated beads. Moreover, only non-specific rupture forces were detected between OPN-coated beads and platelets incubated with anti-αvmut. These results demonstrate the successful application of computational methods to design a soluble peptide that specifically recognizes the TM domain of αv in platelets membranes, even when a 400-fold excess of the homologous integrin subunit αIIb is present. Further, because the peptide binds to the site on the αv TM domain that interacts with the β3 TM helix and activates αvβ3, these results strongly support the hypothesis that separation of the αv and β3 TM domains regulates the function of this integrin.

2011 ◽  
Vol 435 (1) ◽  
pp. 187-196 ◽  
Author(s):  
Valerie A. Novakovic ◽  
David B. Cullinan ◽  
Hironao Wakabayashi ◽  
Philip J. Fay ◽  
James D. Baleja ◽  
...  

Factor VIII functions as a cofactor for Factor IXa in a membrane-bound enzyme complex. Membrane binding accelerates the activity of the Factor VIIIa–Factor IXa complex approx. 100000-fold, and the major phospholipid-binding motif of Factor VIII is thought to be on the C2 domain. In the present study, we prepared an fVIII-C2 (Factor VIII C2 domain) construct from Escherichia coli, and confirmed its structural integrity through binding of three distinct monoclonal antibodies. Solution-phase assays, performed with flow cytometry and FRET (fluorescence resonance energy transfer), revealed that fVIII-C2 membrane affinity was approx. 40-fold lower than intact Factor VIII. In contrast with the similarly structured C2 domain of lactadherin, fVIII-C2 membrane binding was inhibited by physiological NaCl. fVIII-C2 binding was also not specific for phosphatidylserine over other negatively charged phospholipids, whereas a Factor VIII construct lacking the C2 domain retained phosphatidyl-L-serine specificity. fVIII-C2 slightly enhanced the cleavage of Factor X by Factor IXa, but did not compete with Factor VIII for membrane-binding sites or inhibit the Factor Xase complex. Our results indicate that the C2 domain in isolation does not recapitulate the characteristic membrane binding of Factor VIII, emphasizing that its role is co-operative with other domains of the intact Factor VIII molecule.


2021 ◽  
Author(s):  
Justin M Westerfield ◽  
Amita Sahoo ◽  
Daiane S Alves ◽  
Brayan Grau ◽  
Alayna Cameron ◽  
...  

The EphA2 receptor is a promising drug target for cancer treatment, since EphA2 activation can inhibit metastasis and tumor progression. It has been recently described that the TYPE7 peptide activates EphA2 using a novel mechanism that involves binding to the single transmembrane domain of the receptor. TYPE7 is a conditional transmembrane (TM) ligand, which only inserts into membranes at neutral pH in the presence of the TM region of EphA2. However, how membrane interactions can activate EphA2 is not known. We systematically altered the sequence of TYPE7 to identify the binding motif used to activate EphA2. With the resulting six peptides, we performed biophysical and cell migration assays that identified a new potent peptide variant. We also performed a mutational screen that determined the helical interface that mediates dimerization of the TM domain of EphA2 in cells. These results, together with molecular dynamic simulations, allowed to elucidate the molecular mechanism that TYPE7 uses to activate EphA2, where the membrane peptide acts as a molecular clamp that wraps around the TM dimer of the receptor. We propose that this binding mode stabilizes the active conformation of EphA2. Our data, additionally, provide clues into the properties that TM ligands need to have in order to achieve activation of membrane receptors.


2020 ◽  
Author(s):  
Hailey I. Edelstein ◽  
Patrick S. Donahue ◽  
Joseph J. Muldoon ◽  
Anthony K. Kang ◽  
Taylor B. Dolberg ◽  
...  

ABSTRACTSynthetic receptors are powerful tools for engineering mammalian cell-based devices. These biosensors enable cell-based therapies to perform complex tasks such as regulating therapeutic gene expression in response to sensing physiological cues. Although multiple synthetic receptor systems now exist, many aspects of receptor performance are poorly understood. In general, it would be useful to understand how receptor design choices influence performance characteristics. In this study, we examined the modular extracellular sensor architecture (MESA) and systematically evaluated previously unexamined design choices, yielding substantially improved receptors. A key finding that might extend to other receptor systems is that the choice of transmembrane domain (TMD) is important for generating high-performing receptors. To provide mechanistic insights, we adopted and employed a Förster resonance energy transfer (FRET)-based assay to elucidate how TMDs affect receptor complex formation and connected these observations to functional performance. To build further insight into these phenomena, we developed a library of new MESA receptors that sense an expanded set of ligands. Based upon these explorations, we conclude that TMDs affect signaling primarily by modulating intracellular domain geometry. Finally, to guide the design of future receptors, we propose general principles for linking design choices to biophysical mechanisms and performance characteristics.


2010 ◽  
Vol 188 (6) ◽  
pp. 891-903 ◽  
Author(s):  
Janet A. Askari ◽  
Christopher J. Tynan ◽  
Stephen E.D. Webb ◽  
Marisa L. Martin-Fernandez ◽  
Christoph Ballestrem ◽  
...  

Integrins undergo global conformational changes that specify their activation state. Current models portray the inactive receptor in a bent conformation that upon activation converts to a fully extended form in which the integrin subunit leg regions are separated to enable ligand binding and subsequent signaling. To test the applicability of this model in adherent cells, we used a fluorescent resonance energy transfer (FRET)–based approach, in combination with engineered integrin mutants and monoclonal antibody reporters, to image integrin α5β1 conformation. We find that restricting leg separation causes the integrin to adopt a bent conformation that is unable to respond to agonists and mediate cell spreading. By measuring FRET between labeled α5β1 and the cell membrane, we find extended receptors are enriched in focal adhesions compared with adjacent regions of the plasma membrane. These results demonstrate definitely that major quaternary rearrangements of β1-integrin subunits occur in adherent cells and that conversion from a bent to extended form takes place at focal adhesions.


Langmuir ◽  
2017 ◽  
Vol 33 (45) ◽  
pp. 12839-12858 ◽  
Author(s):  
Yi Han ◽  
M. Omair Noor ◽  
Abootaleb Sedighi ◽  
Uvaraj Uddayasankar ◽  
Samer Doughan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document